Navigation Links
New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
Date:12/10/2007

ressure.

LEVITRA is not recommended for patients with uncontrolled hypertension (>170/110 mmHg).

In men for whom sexual activity is not recommended because of their underlying cardiovascular status, any treatment for erectile dysfunction, including LEVITRA, generally should not be used.

In patients taking certain CYP3A4 inhibitors (eg, ritonavir, indinavir, saquinavir, atazanavir, ketoconazole, itraconazole, erythromycin, and clarithromycin), lower doses of LEVITRA are recommended, and time between doses of LEVITRA may need to be extended. See prescribing information for LEVITRA for dosing guidance.

In clinical trials, the most commonly reported adverse events with LEVITRA were headache, flushing, and rhinitis. Adverse events were generally transient.

Nonarteritic anterior ischemic optic neuropathy (NAION) has been reported rarely postmarketing in temporal relationship with the use of PDE5 inhibitors, including LEVITRA. Sudden loss of hearing, sometimes with tinnitus and dizziness, also has been reported rarely in temporal association with the use of PDE5 inhibitors, including LEVITRA. It is not possible to determine if these events are related to PDE5 inhibitors or to other factors. Physicians should advise patients to stop use of PDE5 inhibitors, including LEVITRA, and seek prompt medical attention in the event of sudden loss of vision or hearing.

The recommended starting dose of LEVITRA is 10 mg. Titrate up to 20 mg or down to 5 mg based on efficacy and side effects.
The maximum recommended dosing frequency is once daily.

LEVITRA is available in 2.5-mg, 5-mg, 10-mg and 20-mg tablets.

For Prescribing Information please visit http://www.levitra.com.

About GlaxoSmithKline

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling peop
'/>"/>

SOURCE Schering-Plough
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... BOTHELL, Wash. and VANCOUVER ... OGXI ) announced today that it will report ... 13, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced the appointment ... Warburg Pincus LLC, to the Amgen Board of Directors. ... and the deep, global experience he brings in the ... Bradway , chairman and chief executive officer of Amgen. "Fred,s breadth ... well." Mr. Hassan has been Partner and Managing ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... At Day 3 And All Subsequent Study Visits - ... Sumitomo Pharma Co., Ltd., (DSP) announced today that positive results ... treatment of patients with schizophrenia have been published in ... multicenter, placebo-controlled trial, involving 180 patients with acute schizophrenia, evaluated ...
... VRUS ) announces management will present at the ... Both conferences will be held in New York, NY. , ... will provide an overview of the company at the Goldman ... 3:10 PM (ET) and at the Needham Conference on Thursday ...
Cached Medicine Technology:Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 3Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 4Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences 2Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences 3
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source ... in Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts the ...
(Date:7/31/2015)... ... 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the ... released this new applicator in the United States as an upgrade to the CoolSmooth ... The original applicator required a 2 hour treatment time. The new CoolSmooth Pro ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... M3 USA ... excited to launch three new Board Exam Courses. , The additions of Gastroenterology, ... Board Exam Prep from MDLinx makes preparing for the exam easy and painless. ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... live lecture on pharmaceutical negligence is now available online at ( http://www.lawline.com/cle/course/its-a-wonderful-life-if-you-receive-the-right-meds-a-discussion-of-pharmaceutical-negligence ... with a 94% approval rating from the nationwide audience. The course ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... Hope IVF , is in pursuit of a visionary image that goes beyond the ... the UAE, New Hope IVF has reached extraordinary heights with dependable patient support, affordable ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3
... Israel, Nov. 29 Elbit Imaging Ltd.,(TASE, Nasdaq: ... November,28, 2007, InSightec Ltd. ("InSightec"), a subsidiary of ... an agreement for an internal,round of financing in ... existing,investors, namely: Elbit Ultrasound (Netherlands) B.V., a fully ...
... Satellite Newsfeed Notification ... Friday, 11/30, WASHINGTON, Nov. 29 , ... more than 19,million Americans. Despite its prevalence, depression ... is a,first-of-its-kind study examining the statistical relationship between ...
... benefit for the female hormone , THURSDAY, Nov. 29 ... which is often given with estrogen in hormone replacement ... U.S. researchers say. , They conducted tests on female ... come to this conclusion. , Treatment with estrogen blocked ...
... Week to Experience the, World,s Most Advanced Laparoscopic Surgery ... ... Congress, CLEVELAND, Ohio, November 29 Simbionix unveiled the,latest module ... Global Congress of Minimally Invasive Gynecology., The LAP Mentor(TM) multidisciplinary ...
... Utah, Nov. 29 Nutraceutical,International Corporation (Nasdaq: NUTR ... and year ended September 30, 2007., Net sales ... to $35.7 million for the same quarter of fiscal ... or $0.23 diluted earnings per,share, compared to net income ...
... 29 InSightec Ltd. today,reported that it has closed ... existing investors: Elbit Imaging Ltd. (Nasdaq: EMITF ), ... Company,(NYSE: GE ), MediTech Advisors LLC ("MTA"), a ... managers of the company., The investment will take ...
Cached Medicine News:Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 2Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 3Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 4Health News:Ranking America's Mental Health: An Analysis of Depression Across the States 2Health News:Ranking America's Mental Health: An Analysis of Depression Across the States 3Health News:Progesterone Won't Shield Women Against Alzheimer's 2Health News:Gynecologists Get First Hands-On Experience With Simbionix LAP Mentor(TM) 2Health News:Nutraceutical Reports 2007 Fiscal Year End Results 2Health News:Nutraceutical Reports 2007 Fiscal Year End Results 3Health News:Nutraceutical Reports 2007 Fiscal Year End Results 4Health News:Nutraceutical Reports 2007 Fiscal Year End Results 5Health News:Nutraceutical Reports 2007 Fiscal Year End Results 6Health News:InSightec Ltd. Announces US$30 Million Investment Round 2Health News:InSightec Ltd. Announces US$30 Million Investment Round 3
... Injectable Drugs is a dynamic new ... and easy to check on the ... the selected drugs, clear compatibility and ... can quickly take clinical action based ...
... Keep up with the latest in scientific ... market intelligence and knowledge resources from CenterWatch. ... to help you monitor and stay abreast ... medicine: Drugs in Clinical Trials, Clinical Trial ...
... Drug Guide for Nurses with Integrated Calculators, ... Co) is a remarkable advance in drug ... the Davis s Drug Guide (9th Edition) ... weight based medications. This product merges many ...
Make better prescribing decisions with this drug interaction analyzer containing over 3,000 brand names with generic equivalents....
Medicine Products: